RNA sequencing distinguishes benign from malignant pancreatic lesions sampled by EUS-guided FNA
Autor: | Brintha K. Enestvedt, Sarah A. Rodriguez, Gennadiy Bakis, Soren Impey, Carl Pelz, Terry K. Morgan, Michael Owens |
---|---|
Rok vydání: | 2016 |
Předmět: |
Male
Pathology medicine.medical_specialty Adenocarcinoma Tertiary care Surgical pathology 03 medical and health sciences 0302 clinical medicine Biopsy medicine Pancreatic mass Humans Radiology Nuclear Medicine and imaging Prospective Studies Prospective cohort study Endoscopic Ultrasound-Guided Fine Needle Aspiration Aged Aged 80 and over medicine.diagnostic_test Sequence Analysis RNA business.industry Gene Expression Profiling Gastroenterology RNA Middle Aged medicine.disease digestive system diseases Pancreatic Neoplasms medicine.anatomical_structure Pancreatitis 030220 oncology & carcinogenesis Female 030211 gastroenterology & hepatology Pancreas business |
Zdroj: | Gastrointestinal Endoscopy. 84:252-258 |
ISSN: | 0016-5107 |
Popis: | Background and Aims EUS-guided FNA (EUS-FNA) is the primary method used to obtain pancreatic tissue for preoperative diagnosis. Accumulating evidence suggests diagnostic and prognostic information may be obtained by gene-expression profiling of these biopsy specimens. RNA sequencing (RNAseq) is a newer method of gene-expression profiling, but published data are scant on the use of this method on pancreas tissue obtained via EUS-FNA. The aim of this study was to determine whether RNAseq of EUS-FNA biopsy samples of undiagnosed pancreatic masses can reliably discriminate between benign and malignant tissue. Methods In this prospective study, consenting adults presented to 2 tertiary care hospitals for EUS of suspected pancreatic mass. Tissue was submitted for RNAseq. The results were compared with cytologic diagnosis, surgical pathology diagnosis, or benign clinical follow-up of at least 1 year. Results Forty-eight patients with solid pancreatic mass lesions were enrolled. Nine samples were excluded because of inadequate RNA and 3 because of final pathologic diagnosis of neuroendocrine tumor. Data from the first 13 patients were used to construct a linear classifier, and this was tested on the final 23 patients (15 malignant and 8 benign lesions). RNAseq of EUS-FNA biopsy samples distinguishes ductal adenocarcinoma from benign pancreatic solid masses with a sensitivity of .87 (range, .58-.98) and specificity of .75 (range, .35-.96). Conclusions This proof-of-principle study suggests RNAseq of EUS-FNA samples can reliably detect adenocarcinoma and may provide a new method to evaluate more diagnostically challenging pancreatic lesions. |
Databáze: | OpenAIRE |
Externí odkaz: |